MARKET

ALGS

ALGS

Aligos Therapeutics, Inc.
NASDAQ
5.75
-0.02
-0.35%
Closed 16:11 07/16 EDT
OPEN
5.77
PREV CLOSE
5.77
HIGH
6.12
LOW
5.61
VOLUME
54.76K
TURNOVER
0
52 WEEK HIGH
13.69
52 WEEK LOW
4.800
MARKET CAP
35.58M
P/E (TTM)
-0.6608
1D
5D
1M
3M
1Y
5Y
1D
Analyst Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target Amid Strengthened HBV Trial Outlook
TipRanks · 3d ago
Aligos Completes Enrollment In Phase 2 Trial Of Pevifoscorvir Sodium For HBV; Stock Down
NASDAQ · 3d ago
Aligos Therapeutics completes enrollment in B-SUPREME study
TipRanks · 3d ago
Aligos completes enrollment in Phase 2 B-SUPREME trial for chronic hepatitis B drug pevifoscorvir sodium
PUBT · 3d ago
Aligos Therapeutics Completes Enrollment Of HBeAg+ Patients In Its Phase 2 B-SUPREME Trial Of Pevifoscorvir Sodium To Treat Chronic Hepatitis B Virus Infection
Benzinga · 3d ago
ALIGOS THERAPEUTICS - TOPLINE SAFETY AND EFFICACY DATA EXPECTED IN LATE Q3 2027
Reuters · 3d ago
Weekly Report: what happened at ALGS last week (0706-0710)?
Weekly Report · 4d ago
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Barchart · 4d ago
More
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Webull offers Aligos Therapeutics Inc stock information, including NASDAQ: ALGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALGS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALGS stock methods without spending real money on the virtual paper trading platform.